Intent to Sole Source - Biolegend Oliogos

The National Institutes of Health, Clinical Center (NIH-CC) issued this special notice of intent to negotiate a sole source contract with Biolegend for custom oligonucleotides. These materials are required by the PACT team at the Clinical Center to perform single-cell copy number analysis using a Tapestri instrument for CAR-T cell products, which supports clinical quality control assays. The procurement is being conducted under the statutory authority of 41 U.S.C. 253(c)(1), as implemented by FAR 6.302-1, identifying Biolegend as the only responsible source capable of satisfying the agency’s requirements.

The requirement is classified under NAICS 325414 for Biological Product (except Diagnostic) Manufacturing and PSC 6550 for In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. There is no set-aside designated for this action, and the primary place of performance is Bethesda, MD. One attachment, a quote titled Quote COLG260327-JM-NIH.pdf, was published with the notice on April 29, 2026.

Responses to this notice, including capability statements from responsible sources, are due by May 8, 2026, at 12:00 PM Eastern Standard Time. Although this is not a request for proposal, the government will consider all responses received by the deadline to determine whether to compete the requirement. This solicitation is identified by number NOI-CC-OLAO-26-004813.